Immunocore Holdings plc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
IMCR$30.99+9.1%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023
Condensed ConsolidatedBalance Sheets
(Unaudited, in thousands, except share and per share data)
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $832,821 | $442,626 |
| Accounts receivable, net | 57,754 | 52,093 |
| Prepaid expenses and other current assets | 31,296 | 29,600 |
| Inventory, net | 4,167 | 4,501 |
| Total current assets | 926,038 | 528,820 |
| Property and equipment, net | 8,380 | 9,215 |
| Operating lease right of use assets, net | 32,812 | 33,520 |
| Deferred tax assets, net | 10,761 | 10,973 |
| Other non-current assets | 15,996 | 14,473 |
| Total assets | $993,987 | $597,001 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $15,501 | $17,798 |
| Accrued expenses and other current liabilities | 138,549 | 119,835 |
| Operating lease liabilities, current | 1,243 | 1,388 |
| Total current liabilities | 155,293 | 139,021 |
| Accrued expenses, non-current | 2,162 | 978 |
| Deferred revenue, non-current | 5,468 | 5,515 |
| Operating lease liabilities, non-current | 33,986 | 34,633 |
| Interest-bearing loans and borrowings | 437,544 | 48,011 |
| Total liabilities | 634,453 | 228,158 |
| Shareholders’ equity | ||
| Ordinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £97,454 and £109,335 shares as of March 31, 2024 and December 31, 2023, respectively, and 50,006,085 and 49,725,649 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively. | 135 | 134 |
| Deferred shares, £0.0001 par value, 5,793,501 shares authorized, issued and outstanding as of March 31, 2024 and December 31, 2023. | 1 | 1 |
| Additional paid-in capital | 1,163,872 | 1,149,643 |
| Accumulated deficit | (769,110) | (744,674) |
| Accumulated other comprehensive loss | (35,364) | (36,261) |
| Total shareholders’ equity | 359,534 | 368,843 |
| Total liabilities and shareholders’ equity | $993,987 | $597,001 |
Condensed Consolidated Statements ofOperations and Comprehensive Loss
(Unaudited, in thousands, except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue: | ||
| Product revenue, net | $70,342 | $51,581 |
| Collaboration revenue | 160 | 3,078 |
| Total revenue | 70,502 | 54,659 |
| Cost and operating expenses: | ||
| Cost of product revenue | (246) | (216) |
| Research and development expense | (57,459) | (36,572) |
| Selling, general and administrative expense | (39,287) | (32,567) |
| Loss from operations | (26,490) | (14,696) |
| Other income (expense): | ||
| Interest income | 8,246 | 3,128 |
| Interest expense | (3,239) | (1,250) |
| Foreign currency loss | (2,406) | (6,013) |
| Other expense, net | (190) | (325) |
| Net loss before income taxes | (24,079) | (19,156) |
| Income tax expense | (357) | (293) |
| Net loss | $(24,436) | $(19,449) |
| Other comprehensive income: | ||
| Exchange differences on translation of foreign operations | 897 | 7,434 |
| Total comprehensive loss | (23,539) | (12,015) |
| Basic and diluted net loss per share | $(0.49) | $(0.40) |
| Basic and diluted weighted-average number of shares outstanding | 49,877,218 | 48,183,771 |
Condensed ConsolidatedStatements of
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.